Product introduction and marketing status of albuterol/budesonide inhalation spray (Airsupra)

Albuterol/budesonide inhalation spray (trade nameAirsupra) is a fixed-dose combination medication designed to treat bronchoconstriction andasthma. The drug combines two active ingredients: the short-acting β2-adrenergic agonist albuterol sulfate and the inhaled corticosteroid bdesonide to form a highly effective treatment regimen. Albuterol rapidly relaxes airway smooth muscles, thereby relieving breathing difficulties caused by bronchoconstriction, while budesonide helps control and prevent asthma attacks by reducing airway inflammation. Airsupra is inhaled through a pressurized metered dose inhaler and can be used by patients at any time as needed to provide timely relief when acute symptoms occur.

Airsupra was approved for medical use in January 2023. This approval marks Airsupra as the first FDA-approved product to combine an inhaled corticosteroid with a short-acting beta-agonist, specifically in the treatment of asthma, where it can be used not only as a controller treatment but also as an effective reliever treatment. This is extremely important for asthma patients as it provides a flexible and convenient medication option to quickly respond to sudden asthma symptoms.

Clinical studies have shown that Airsupra is effective in reducing the risk of severe attacks in asthma patients. Studies have shown that compared with albuterol alone, Airsupra can significantly prolong the time to the first severe asthma attack, reduce the frequency of acute attacks in patients, thereby improving quality of life. In this case, patients no longer need to frequently use multiple drugs to manage their condition, but can achieve more efficient symptom control with Airsupra.

AlthoughAirsupra has good efficacy, there are some common side effects that you need to be aware of when using this drug. For example, patients may experience headaches, oral candida infections, coughing, and difficulty speaking. Therefore, before starting use, patients should consult their doctor in detail to understand their health status and the suitability of the drug. In addition, Airsupra is not suitable for use in patients who are allergic to albuterol, budesonide or other ingredients.

In short, albuterol/budesonideinhalation spray (Airsupra) provides an effective treatment option for asthma patients. Its unique combination of drugs and flexible medication methods allow patients to quickly obtain relief when symptoms occur and reduce the risk of severe attacks. As this new treatment becomes more widely available, patients' quality of life is expected to improve significantly, especially in the management of chronic respiratory diseases.

Currently, salbutamol/budesonide inhalation spray has not yet been launched in China, and domestic patients cannot directly purchase this drug for the time being. If patients want to obtain more knowledge about this drug, it is recommended to consult a medical consultant.

Reference link: https://en.wikipedia.org/wiki/Salbutamol/budesonide